At Okairos, we believe in pushing the boundaries of science in the search for breakthroughs. Our scientists are working on ground-breaking projects in our effort to create novel and important new vaccines.
Our efforts are focused on the discovery and development of novel genetic vaccines against a range of infectious diseases and cancer, using the company’s proprietary adenovirus vector technology.
Our adenovirus vector platform is generating a pipeline of T-cell vaccines against a range of infectious diseases. We have also developed a proprietary packaging cell line, Procell92, a crucial platform to support the development and commercialization of our vaccines.